This molecular genetics study compared gene expression patterns in active MS lesions versus normal-appearing brain tissue from the same patients, revealing that MS is not simply a disease of visible lesions but rather a widespread nervous system disorder. Using microarray technology, researchers identified 123 genes abnormally expressed in lesions and 47 genes abnormally expressed in normal-appearing tissue. Notably, genes related to immune system activation were dysregulated in both lesion and normal tissue, suggesting that the disease process affects the entire brain rather than just visible inflamed areas. The pattern showed higher expression of genes for immune protein synthesis and nerve cell development in lesions, with immune dysfunction equally present in apparently normal tissue.
This research fundamentally changes understanding of MS from a focal disease (lesions in specific locations) to a systemic brain disorder affecting the entire central nervous system at the molecular level. The finding that immune genes are abnormally activated even in tissue appearing normal on imaging has major implications for disease monitoring and treatment planning. It explains why patients with few visible lesions can still experience significant symptoms and cognitive decline—widespread molecular changes precede or occur independently of visible inflammation. For treatment planning, this suggests that targeting only visible lesions misses the broader disease process; therapies must address the systemic immune dysregulation affecting the entire nervous system. The research validates the importance of treating MS aggressively even when lesion burden appears low, and supports developing biomarkers based on molecular changes rather than relying solely on imaging. It also suggests that remyelination therapies must address the broader tissue environment, not just repairing individual lesions.
